Taiko Pharmaceutical Co (TSE:4574) Change In Receivables: 円0 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4574 Taiko Pharmaceutical Co Ltd TSE:4574
64 GF Score
Price 円260.00
GF Value 円265.16
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Taiko Pharmaceutical Co Change In Receivables?

Taiko Pharmaceutical Co TSE:4574 -1.14% 64 Change In Receivables is 円0 Mil as of Jun. 2026. GuruFocus rates TSE:4574 with a GF Score™ of 64/100 and a GF Value™ of 円265.16 (Fairly Valued). The stock has 4 warning signs investors should review.

Taiko Pharmaceutical Co's change in receivables for the quarter that ended in Jun. 2026 was 円0 Mil. It means Taiko Pharmaceutical Co's Accounts Receivable stayed the same from Mar. 2026 to Jun. 2026 .

Taiko Pharmaceutical Co's change in receivables for the fiscal year that ended in Dec. 2025 was 円-23 Mil. It means Taiko Pharmaceutical Co's Accounts Receivable increased by 円23 Mil from Dec. 2024 to Dec. 2025 .

Taiko Pharmaceutical Co's Accounts Receivable for the quarter that ended in Jun. 2026 was 円1,934 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Taiko Pharmaceutical Co's liquidation value for the three months ended in Jun. 2026 was 円2,903 Mil.

Taiko Pharmaceutical Co  (TSE:4574) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Taiko Pharmaceutical Co's Days Sales Outstanding for the quarter that ended in Jun. 2026 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=1934/0*91
=

2. In Ben Graham's calculation of liquidation value, Taiko Pharmaceutical Co's accounts receivable are only considered to be worth 75% of book value:

Taiko Pharmaceutical Co's liquidation value for the quarter that ended in Jun. 2026 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=3166-2666+0.75 * 1934+0.5 * 1904
=2,903

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Taiko Pharmaceutical Co Change In Receivables Related Terms

Taiko Pharmaceutical Co Change In Receivables Historical Data

* Premium members only.

The historical data trend for Taiko Pharmaceutical Co's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Taiko Pharmaceutical Co Change In Receivables Chart

Taiko Pharmaceutical Co Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Dec21 Dec22 Dec23 Dec24 Dec25
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3,899.00 2,315.00 -175.00 -411.00 -23.00

Taiko Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
TSE:4574
64GF Score
Taiko Pharmaceutical Co Ltd TSE:4574
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Taiko Pharmaceutical Co Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of 円0 Mil mean?
Taiko Pharmaceutical Co (TSE:4574) has a Change In Receivables of 円0 Mil as of Jun. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Taiko Pharmaceutical Co and its competitors.
Is Taiko Pharmaceutical Co's Change In Receivables too high?
Taiko Pharmaceutical Co's current Change In Receivables is 円0 Mil. Overall, Taiko Pharmaceutical Co has a GF Score™ of 64/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Taiko Pharmaceutical Co's Change In Receivables compare to ZTS?
Taiko Pharmaceutical Co's Change In Receivables of 円0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Drug Manufacturers company?
A good Change In Receivables depends on the Drug Manufacturers industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Taiko Pharmaceutical Co and its competitors. Taiko Pharmaceutical Co's current Change In Receivables is 円0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Taiko Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Taiko Pharmaceutical Co (TSE:4574) is currently considered Fairly Valued. The stock's GF Value™ is 円265.16, compared to a current price of 円260.00 — trading 1.9% below its estimated fair value. The current Change In Receivables is 円0 Mil. Taiko Pharmaceutical Co's overall GF Score™ is 64/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For Taiko Pharmaceutical Co (TSE:4574), the current Change In Receivables is 円0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Taiko Pharmaceutical Co (TSE:4574) Overvalued in 2026?

Based on GuruFocus' analysis, Taiko Pharmaceutical Co stock appears to be undervalued. The current stock price of 円260.00 is trading 1.9% below its estimated GF Value™ of 円265.16. GuruFocus considers Taiko Pharmaceutical Co to be Fairly Valued.

Key valuation signals for TSE:4574:

  • Change In Receivables: 円0 Mil
  • GF Value™: 円265.16 vs. price of 円260.00 (1.9% below fair value)
  • GF Score™: 64/100 with 4 warning signs

No single metric tells the full story. See the TSE:4574 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Taiko Pharmaceutical Co Business Description

Address 1-4-1 Nishihonmachi, 16th Floor, ORIX Honmachi Building, Nishi-ku, Osaka, JPN, 564-0032
Taiko Pharmaceutical Co Ltd operates in three segments, namely Pharmaceutical, Infection Control, and Others. The majority of its revenue comes from Infection Control, which is into manufacturing and sales of sanitation control products, including Cleverin, Cleverin LED, and Cleverin Generator LISPASS. The pharmaceutical segment is into the manufacturing and sales of OTC medicines and designated quasi-drugs. Other business includes manufacturing and sales of wood vinegar-based products.
64GF Score

Get the complete analysis for TSE:4574

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円260.00
Price
円265.16
GF Value